Subject(s)
Urinary Bladder Neoplasms/surgery , Adult , Aged , Female , Humans , Male , Middle Aged , Preoperative Care , Radiation Dosage , Urinary Bladder Neoplasms/radiotherapySubject(s)
Mediastinal Neoplasms/radiotherapy , Radiotherapy Dosage , Vena Cava, Superior/radiation effects , Adolescent , Adult , Aged , Carcinoma, Bronchogenic/radiotherapy , Carcinoma, Squamous Cell/radiotherapy , Child , Constriction, Pathologic/radiotherapy , Female , Humans , Lung Neoplasms/radiotherapy , Lymphoma/radiotherapy , Male , Mediastinal Neoplasms/complications , Middle AgedSubject(s)
Carcinoma, Squamous Cell/radiotherapy , Mouth Neoplasms/radiotherapy , Pharyngeal Neoplasms/radiotherapy , Adult , Aged , Cesium Radioisotopes/therapeutic use , Cobalt Radioisotopes/therapeutic use , Female , Humans , Male , Middle Aged , Radioisotope Teletherapy , Retrospective Studies , RomaniaABSTRACT
Study of survival amongst a group of 101 patients with epithelial tumours of the nasopharynx treated by cobalt irradiation between 1967 and 1972 indicates the prognostic significance of the following factors: the histological type, extension of the tumour, the degree of lymph node involvement, age and sex. The optimal dose is 1,800 to 2,000 rets NSD and should be modified in the light of these factors, and above all the histological type and the tumour category. Cumulative survival for all cases was 36% at 5 years, with a more favourable prognosis in lympho-epitheliomas in comparison with spindle cell epitheliomas.
Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Carcinoma/radiotherapy , Nasopharyngeal Neoplasms/radiotherapy , Adolescent , Adult , Aged , Carcinoma/mortality , Carcinoma, Squamous Cell/mortality , Child , Cobalt Radioisotopes , Female , Humans , Male , Middle Aged , Nasopharyngeal Neoplasms/mortality , Prognosis , Radioisotope Teletherapy , Retrospective StudiesABSTRACT
Cobaltotherapy was applied in 194 cases of bronchopulmonary cancer in the Oncologic Institute of Cluj-Napoca, during the 1967--1974 period. The mean survial was of 15 months, the results being influenced by the histologic type and locoregional extent apraised on the basis of the TNM classification proposed by the American Joint Committe for Cancer Staging and End Result Reporting. The mean survival after irradiation was of 9.7% and 5.1% at 3 and 5 years respectively. Standardization of the cases according to the TNM criteria showed the advanced stage of the patients referred for radiotherapy, proving a useful tool for establishing the prognosis and therapeutical indications. Next to the histological type and TNM category, the efficiency of radiotherapy is also influenced by the size and shape of the tumor, which conditions the irradiation technique. The central tumours or those of the upper lobes may be irradiated by small 150 cm2 beams and are the only ones that benefit by radical radiotherapy, the survival rate at 2 and 5 years being 12.3% and 7.6% respectively. In all the other cases the prognosis is more reserved, suggesting the necessity of associating chemotherapy or immunotherapy for improving the results.
Subject(s)
Adenocarcinoma/radiotherapy , Carcinoma, Squamous Cell/radiotherapy , Lung Neoplasms/radiotherapy , Radioisotope Teletherapy , Aged , Cobalt Radioisotopes , Female , Humans , Male , Middle Aged , Neoplasm Metastasis , Prognosis , Radiotherapy DosageABSTRACT
The authors present the results of telecobalt therapy in 194 patients with malignant lung tumours treated between 1967 and 1971. The 3- and 5-year survivals were 9.7 and 5.4% respectively, with an average survival of 15 months. The results obtained depend on the microscopy, the clinical staging and on the irradiation techniques possible; several prognostic groups may be distinguished.
